AstraZeneca’s Olaparib Prolongs Remission in Ovarian Cancer
This article is for subscribers only.
AstraZeneca Plc’s experimental pill olaparib prolonged remission rates in women with ovarian cancer, slowing progression of the deadly disease, researchers said.
The medication, designed to prevent tumor cells from repairing damage caused naturally or by chemotherapy, helped women with serous ovarian cancer live for 8.4 months before the tumor resumed growing, compared with 4.8 months for those given a placebo. All 264 women were in remission when they started the company-funded study, a time when no drugs are typically taken.